会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明专利
    • Fatty acid fumarate derivatives and their uses
    • NZ601698A
    • 2015-04-24
    • NZ60169811
    • 2011-01-07
    • CATABASIS PHARMACEUTICALS INC
    • MILNE JILL CSMITH JESSE JVU CHI BBEMIS JEAN EJIROUSEK MICHAEL R
    • A01N37/00A01N37/18A61K31/16A61K31/22C07C233/20C07C233/38C07C233/49
    • Disclosed are fatty acid fumarate derivatives as represented by the general formulae (I) or (II), or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, or stereoisomer thereof; wherein each W1,W2, W1′ and W2′ is independently null, O, S, NH, or NR, or W1 and W2, or W1′ and W2′ can be taken together to form an optionally substituted imidazolidine or piperazine group; each n, o, p, q, n′, o′, p′, and q′ is independently 0, 1, or 2; each m and m′ is independently 0, 1, 2, or 3; each Z and Z′ is independently -H, or a fatty acid moiety, or a 1,2-dithiolane substituted alkyl derivative all as defined herein; provided that at least one of Z and Z′ is not H; and wherein the remaining substituents are as defined herein. Representative compounds include (E)-methyl 4-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethylamino)-4-oxobut-2-enoate, (E)-methyl 4-(2-(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenamidoethylamino)-4-oxobut-2-enoate, (S)-6-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)-2-((E)-4-methoxy-4-oxobut-2-enamido)hexanoic acid, (S)-1,3-dihydroxypropan-2-yl 6-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)-2-((E)-4-methoxy-4-oxobut-2-enamido)hexanoate, (S)-5-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)-2-((E)-4-methoxy-4-oxobut-2-enamido)pentanoic acid, (S)-1,3-dihydroxypropan-2-yl 5-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)-2-((E)-4-methoxy-4-oxobut-2-enamido)pentanoate, and (S)-1,3-dihydroxypropan-2-yl 2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)-5-((E)-4-ethoxy-4-oxobut-2-enamido)pentanoate. Also disclosed is a pharmaceutical composition comprising a compound as defined above, and a pharmaceutically acceptable carrier, for use in the treatment of a neurodegenerative disease, an inflammation, or an inflammatory disease.